1-4 of 4
Stephanie Dieck
Close
Sort by
Journal Articles

Reduction of Erythropoiesis in MDS with 5q Deletion Is Associated with Aberrant SPARC and TNF-Alpha Gene Expression and Predicts the Efficacy of Lenalidomide Therapy.

Guntram Buesche, MD, Aristoteles Giagounidis, MD, Gudrun Göhring, Brigitte Schlegelberger, Stephanie Dieck, Robert Knight, MD, Carlo Aul, MD, Hans H. Kreipe, MD
Journal: Blood
Blood (2012) 120 (21): 2826.
https://doi.org/10.1182/blood.V120.21.2826.2826
Published: 2012
Journal Articles

Prognosis of Low- or Intermediate-1-Risk MDS with Del(5q) Chromosome Abnormality During Lenalidomide Therapy Depends on the Capacity of the Neoplastic Stem Cell to Differentiate Into Maturing Erythroid Committed Stem Cells,

Guntram Buesche, M.D., Aristoteles Giagounidis, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, M.D., Stephanie Dieck, Robert Knight, MD, Carlo Aul, MD, Hans H. Kreipe, MD
Journal: Blood
Blood (2011) 118 (21): 3819.
https://doi.org/10.1182/blood.V118.21.3819.3819
Published: 2011
Journal Articles

Anti-Angiogenic in-Vivo Effect of Lenalidomide and Its Impact On Neoplastic and Non-Neoplastic Hematopoiesis in MDS with Del(5q) Chromosome Abnormality.

Guntram Buesche, MD, Stephanie Dieck, Aristoteles Giagounidis, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Robert Knight, MD, Carlo Aul, MD, Hans Kreipe, MD
Journal: Blood
Blood (2009) 114 (22): 3800.
https://doi.org/10.1182/blood.V114.22.3800.3800
Published: 2009
Journal Articles

Anti-Angiogenic In Vivo Effect of Lenalidomide (CC-5013) in Myelodysplastic Syndrome with del(5q) Chromosome Abnormality and Its Relation to the Course of Disease.

Guntram Buesche, Stephanie Dieck, Aristoteles Giagounidis, Oliver Bock, Ludwig Wilkens, PD, Brigitte Schlegelberger, Robert Knight, John Bennett, Carlo Aul, Hans H. Kreipe
Journal: Blood
Blood (2005) 106 (11): 372.
https://doi.org/10.1182/blood.V106.11.372.372
Published: 2005